NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of treatment for patients suffering from debilitating neurodegenerative diseases. Its lead product, PrimeC, is a novel oral formulation that has completed Phase IIa clinical trials for the treatment of amyotrophic lateral sclerosis. The company's preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.
Show more...
FAQ
NeuroSense Therapeutics 今天的股價是多少?▼
NRSN.BOATS 目前價格為 $0.77 USD,過去 24 小時上漲了 +5.78%。在圖表上更密切關注 NeuroSense Therapeutics 股價表現。
NeuroSense Therapeutics 的股票代號是什麼?▼
根據交易所不同,股票代號可能會有所差異。例如,在 交易所,NeuroSense Therapeutics 的股票以代號 NRSN.BOATS 進行交易。
NeuroSense Therapeutics 的市值是多少?▼
今天 NeuroSense Therapeutics 的市值為 19M
NeuroSense Therapeutics 下一次財報日期是什麼時候?▼
NeuroSense Therapeutics 將於 June 22, 2026 公布下一次財報。
NeuroSense Therapeutics 去年的營收是多少?▼
NeuroSense Therapeutics 去年的營收為 0USD。
NeuroSense Therapeutics 去年的淨利是多少?▼
NRSN.BOATS 去年的淨收益為 -20.42MUSD。
NeuroSense Therapeutics 有多少名員工?▼
截至 April 01, 2026,公司共有 17 名員工。
NeuroSense Therapeutics 位於哪個產業?▼
NeuroSense Therapeutics從事於Health Care產業。
NeuroSense Therapeutics 何時完成拆股?▼
NeuroSense Therapeutics 最近沒有進行任何拆股。
NeuroSense Therapeutics 的總部在哪裡?▼
NeuroSense Therapeutics 的總部位於 IL 的 Herzliya。